Abstract: A method for desalinating a brine includes the use of a cooled intermediate-cold-liquid (ICL), which combines with the brine in a crystallization or freezing tank, where the brine and cooled ICL are contacted for a time sufficient to produce a slurry of ice, brine, and ICL. The method includes steps for separating the ICL, ice and brine, and melting the separated ice to form a volume of desalinated water. The method is significant in that it produces desalinated liquid water and solid salts. The combination of superior heat transfer with high quality purified water and competitive desalination economy makes the disclosed freeze desalination technology an attractive solution for desalination of highly concentrated brines produced in a variety of industries, including but not limited to the oil and gas industry and reject brine management.

Abstract: A method for desalinating a brine includes the use of a cooled intermediate-cold-liquid (ICL), which combines with the brine in a crystallization or freezing tank to produce a slurry of ice, brine, and ICL. The method includes steps for separating the ICL, ice and brine, and returning the separated ICL to the source of cooled ICL tank. The method concludes with the steps of passing the separated brine to the crystallization tank, and melting the separated ice to form desalinated water. The method is significant in that it produces desalinated liquid water and solid salts. The combination of superior heat transfer with high quality purified water and competitive desalination economy makes the disclosed freeze desalination technology an attractive solution for desalination of highly concentrated brines produced in a variety of industries, including but not limited to the oil and gas industry and reject brine management.

Abstract: Provided are keratin BD-4, an encoding nucleic acid molecule thereof, an expression vector, a host cell, and a pharmaceutical composition containing the keratin. The keratin BD-4 can be used for preparing drugs having antipyretic and analgesic, antitussive and expectorant, and antiepileptic effects.

Abstract: Computing devices, computer-readable storage media, and computer-implemented methods are disclosed for prediction of capacity. In a central tier, central-tier benchmark values are generated from benchmark testing performed on different test configurations in a reference execution environment. In a deployment tier, deployment-tier benchmark values are generated from benchmark testing performed on a baseline deployed configuration in many execution environments. A sizing model is learned from the central-tier benchmark values to predict execution platform requirements given a set of workload input parameters. A performance model is learned from the deployment-tier and the central-tier benchmark values to predict a performance delta value reflecting relative performance between a particular execution environment and the reference execution environment. The performance delta value is used to adjust predicted execution platform requirements to tailor the prediction to a particular execution environment.

Abstract: The present invention provides a keratin BD-3, a nucleic acid molecule encoding same, an expression vector, a host cell, a preparation method therefor, and a pharmaceutical composition contained the keratin BD-3. The keratin BD-3 can be used in the preparation of medicament for antipyretic, analgesic, antitussive, expectorant, anticonvulsant, antiepileptic, anti-hypertension, anti-inflammatory, and antiviral.

Abstract: The present disclosure provides an identification method of two parents of a Nymphaea hybrid based on sequences of internal transcribed spacer (ITS) and matK, and belongs to the technical field of plant molecular identification. In the present disclosure, the identification method includes: based on Sanger sequencing, obtaining an ITS sequence of a nuclear genome fragment inherited from the two parents and a matK sequence of a chloroplast genome fragment inherited from a maternal line in the Nymphaea hybrid; subjecting ITS and matK sequences downloaded from a GenBank to strict screening, and establishing a database of the ITS and matK sequence of the Nymphaea; aligning ITS and matK sequences of the Nymphaea of the parents to be determined with respective database, and constructing a neighbor-joining tree based on a genetic distance; and checking specific loci to obtain information on male and female parents of the Nymphaea to be determined.

Abstract: Provided are a method for preparing L-glufosinate and the intermediate compounds of formula (V) and formula (III).

Abstract: The present invention provides a device for peening by coupling a laser shock wave and an ultrasonic shock wave in real time. The device includes a synchronization device, a laser device, two ultrasonic shock devices, a working platform and a control system. An upper casing is supported above a base through second hydraulic cylinders. Two supporting beams are provided under the upper casing through the second hydraulic cylinders. Limiting slide rails are provided under the upper casing through first hydraulic cylinders. The two ultrasonic shock devices are connected through the synchronization device, which is configured to synchronize movement and rotation of the two ultrasonic shock devices. The laser device is configured to generate a laser beam to pass through the upper casing and irradiate a surface of a workpiece. The control system controls the laser device to lag behind the two ultrasonic shock devices to perform laser shock.

Abstract: Provided are a method for preparing L-glufosinate and the intermediate compounds of formula (V) and formula (III).

Abstract: The present invention provides a keratin BD-10, an encoding nucleic acid molecule, an expression vector, a host cell thereof, a preparation method for BD-10, and a pharmaceutical composition containing the keratin BD-10. Also provides the use of the keratin BD-10, nucleic acid molecule, expression vector, host cell or pharmaceutical composition in the preparation of medicament for antipyretic, analgesic, antitussive, expectorant, anticonvulsant, antiepileptic, anti-hypertension, anti-inflammatory, and antiviral.

Abstract: A water treatment system is configured to remove salt from a feed brine. The water treatment system includes a primary freezing chamber configured to receive the feed brine and a source of cooled intermediate cold liquid connected to the primary freezing chamber. The cooled intermediate cold liquid and feed brine are mixed within the primary freezing chamber, where ice particles are formed. The water treatment system includes a rotary separator connected to a discharge from the primary freezing chamber. The rotary separator is configured to separate solid ice particles from liquid components in the discharge from the primary freezing chamber. In some embodiments, the rotary separator includes a mesh inner filter tube that is configured for rotation within a solid outer filter tube, where the mesh inner filter tube allows liquid components to drain into the outer filter tube while conveying solid ice particles to an ice recovery tank.

Abstract: Provided are keratin BD-4, an encoding nucleic acid molecule thereof, an expression vector, a host cell, and a pharmaceutical composition containing the keratin. The keratin BD-4 can be used for preparing drugs having antipyretic and analgesic, antitussive and expectorant, and antiepileptic effects.

Abstract: Disclosed are a method and an apparatus for generating patent summary information, and an electronic device and a computer readable medium. The method for generating patent summary information includes: extracting technical problem information from a target patent document; extracting solution information from the target patent document; and generating the patent summary information based on the technical problem information and the solution information.

Abstract: Provided are a method for preparing L-glufosinate and the intermediate compounds of formula (V) and formula (III).

Abstract: The present invention provides a device for peening by coupling a laser shock wave and an ultrasonic shock wave in real time. The device includes a synchronization device, a laser device, two ultrasonic shock devices, a working platform and a control system. An upper casing is supported above a base through second hydraulic cylinders. Two supporting beams are provided under the upper casing through the second hydraulic cylinders. Limiting slide rails are provided under the upper casing through first hydraulic cylinders. The two ultrasonic shock devices are connected through the synchronization device, which is configured to synchronize movement and rotation of the two ultrasonic shock devices. The laser device is configured to generate a laser beam to pass through the upper casing and irradiate a surface of a workpiece. The control system controls the laser device to lag behind the two ultrasonic shock devices to perform laser shock.

Abstract: Embodiments of the present disclosure provides a method and a system for labeling and retrieving the protection scope of claims and for labeling information of a gene sequence, wherein the method includes: recognizing a gene sequence from the claims of the current patent application; extracting descriptive texts of the gene sequence from the claims based on a preset keyword; determining similarity information of the gene sequence based on the extracted descriptive texts, and labeling the scope of the claims of the gene sequence based on the similarity information. In the technical solutions provide in the embodiments of the present disclosure, a sequence retrieval can be performed in a patent library, and the accuracy of the gene sequence retrieval can be improved.